Leerink Partners Downgrades CVS Health to Market Perform, Announces $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Michael Cherny downgraded CVS Health (NYSE:CVS) from Outperform to Market Perform and set a $60 price target.
May 01, 2024 | 6:44 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
CVS Health was downgraded by Leerink Partners from Outperform to Market Perform with a new price target of $60.
Analyst downgrades typically lead to a negative short-term reaction in the stock price as they suggest a less optimistic outlook on the company's future performance. The new price target of $60 could also adjust market expectations.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100